Fig. 3.

Percentage of patients remaining in the study under the assumption that: equal percentage of patients in early and delayed start group in the study need additional symptomatic therapy (scenario = 1), higher percentage of patients in delayed start group need additional symptomatic therapy due to initial placebo treatment(scenario = 2), and higher percentage of patients in early start group have tolerability issues with drug followed by a similar percentage of patients in delay start group when they are switched from placebo to drug (scenario = 3)